Borja Del Pozo Cruz1, Matthew N Ahmadi2, I-Min Lee3,4, Emmanuel Stamatakis2. 1. Department of Sports Science and Clinical Biomechanics, Centre for Active and Healthy Ageing, University of Southern Denmark, Odense, Denmark. 2. Faculty of Medicine and Health, Charles Perkin Centre, School of Health Sciences, The University of Sydney, Camperdown, New South Wales, Australia. 3. Division of Preventive Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Abstract
Importance: Recommendations for the number of steps per day may be easier to enact for some people than the current time- and intensity-based physical activity guidelines, but the evidence to support steps-based goals is limited. Objective: To describe the associations of step count and intensity with all-cause mortality and cancer and cardiovascular disease (CVD) incidence and mortality. Design, Setting, and Participants: This population-based prospective cohort study used data from the UK Biobank for 2013 to 2015 (median follow-up, 7 years) and included adults 40 to 79 years old in England, Scotland, and Wales. Participants were invited by email to partake in an accelerometer study. Registry-based morbidity and mortality were ascertained through October 2021. Data analyses were performed during March 2022. Exposures: Baseline wrist accelerometer-measured daily step count and established cadence-based step intensity measures (steps/min): incidental steps, (<40 steps/min), purposeful steps (≥40 steps/min); and peak-30 cadence (average steps/min for the 30 highest, but not necessarily consecutive, min/d). Main Outcomes and Measures: All-cause mortality and primary and secondary CVD or cancer mortality and incidence diagnosis. For cancer, analyses were restricted to a composite cancer outcome of 13 sites that have a known association with reduced physical activity. Cox restricted cubic spline regression models were used to assess the dose-response associations. The linear mean rate of change (MRC) in the log-relative hazard ratio for each outcome per 2000 daily step increments were also estimated. Results: The study population of 78 500 individuals (mean [SD] age, 61 [8] years; 43 418 [55%] females; 75 874 [97%] White individuals) was followed for a median of 7 years during which 1325 participants died of cancer and 664 of CVD (total deaths 2179). There were 10 245 incident CVD events and 2813 cancer incident events during the observation period. More daily steps were associated with a lower risk of all-cause (MRC, -0.08; 95% CI, -0.11 to -0.06), CVD (MRC, -0.10; 95% CI, -0.15 to -0.06), and cancer mortality (MRC, 95% CI, -0.11; -0.15 to -0.06) for up to approximately 10 000 steps. Similarly, accruing more daily steps was associated with lower incident disease. Peak-30 cadence was consistently associated with lower risks across all outcomes, beyond the benefit of total daily steps. Conclusions and Relevance: The findings of this population-based prospective cohort study of 78 500 individuals suggest that up to 10 000 steps per day may be associated with a lower risk of mortality and cancer and CVD incidence. Steps performed at a higher cadence may be associated with additional risk reduction, particularly for incident disease.
Importance: Recommendations for the number of steps per day may be easier to enact for some people than the current time- and intensity-based physical activity guidelines, but the evidence to support steps-based goals is limited. Objective: To describe the associations of step count and intensity with all-cause mortality and cancer and cardiovascular disease (CVD) incidence and mortality. Design, Setting, and Participants: This population-based prospective cohort study used data from the UK Biobank for 2013 to 2015 (median follow-up, 7 years) and included adults 40 to 79 years old in England, Scotland, and Wales. Participants were invited by email to partake in an accelerometer study. Registry-based morbidity and mortality were ascertained through October 2021. Data analyses were performed during March 2022. Exposures: Baseline wrist accelerometer-measured daily step count and established cadence-based step intensity measures (steps/min): incidental steps, (<40 steps/min), purposeful steps (≥40 steps/min); and peak-30 cadence (average steps/min for the 30 highest, but not necessarily consecutive, min/d). Main Outcomes and Measures: All-cause mortality and primary and secondary CVD or cancer mortality and incidence diagnosis. For cancer, analyses were restricted to a composite cancer outcome of 13 sites that have a known association with reduced physical activity. Cox restricted cubic spline regression models were used to assess the dose-response associations. The linear mean rate of change (MRC) in the log-relative hazard ratio for each outcome per 2000 daily step increments were also estimated. Results: The study population of 78 500 individuals (mean [SD] age, 61 [8] years; 43 418 [55%] females; 75 874 [97%] White individuals) was followed for a median of 7 years during which 1325 participants died of cancer and 664 of CVD (total deaths 2179). There were 10 245 incident CVD events and 2813 cancer incident events during the observation period. More daily steps were associated with a lower risk of all-cause (MRC, -0.08; 95% CI, -0.11 to -0.06), CVD (MRC, -0.10; 95% CI, -0.15 to -0.06), and cancer mortality (MRC, 95% CI, -0.11; -0.15 to -0.06) for up to approximately 10 000 steps. Similarly, accruing more daily steps was associated with lower incident disease. Peak-30 cadence was consistently associated with lower risks across all outcomes, beyond the benefit of total daily steps. Conclusions and Relevance: The findings of this population-based prospective cohort study of 78 500 individuals suggest that up to 10 000 steps per day may be associated with a lower risk of mortality and cancer and CVD incidence. Steps performed at a higher cadence may be associated with additional risk reduction, particularly for incident disease.
Authors: Matthew N Ahmadi; Nicole Nathan; Rachel Sutherland; Luke Wolfenden; Stewart G Trost Journal: J Sports Sci Date: 2019-12-11 Impact factor: 3.337
Authors: William E Kraus; Kathleen F Janz; Kenneth E Powell; Wayne W Campbell; John M Jakicic; Richard P Troiano; Kyle Sprow; Andrea Torres; Katrina L Piercy Journal: Med Sci Sports Exerc Date: 2019-06 Impact factor: 5.411
Authors: Thomas Yates; Steven M Haffner; Phillip J Schulte; Laine Thomas; Kim M Huffman; Connie W Bales; Robert M Califf; Rury R Holman; John J V McMurray; M Angelyn Bethel; Jaakko Tuomilehto; Melanie J Davies; William E Kraus Journal: Lancet Date: 2013-12-20 Impact factor: 79.321
Authors: Amanda E Paluch; Shivangi Bajpai; David R Bassett; Mercedes R Carnethon; Ulf Ekelund; Kelly R Evenson; Deborah A Galuska; Barbara J Jefferis; William E Kraus; I-Min Lee; Charles E Matthews; John D Omura; Alpa V Patel; Carl F Pieper; Erika Rees-Punia; Dhayana Dallmeier; Jochen Klenk; Peter H Whincup; Erin E Dooley; Kelley Pettee Gabriel; Priya Palta; Lisa A Pompeii; Ariel Chernofsky; Martin G Larson; Ramachandran S Vasan; Nicole Spartano; Marcel Ballin; Peter Nordström; Anna Nordström; Sigmund A Anderssen; Bjørge H Hansen; Jennifer A Cochrane; Terence Dwyer; Jing Wang; Luigi Ferrucci; Fangyu Liu; Jennifer Schrack; Jacek Urbanek; Pedro F Saint-Maurice; Naofumi Yamamoto; Yutaka Yoshitake; Robert L Newton; Shengping Yang; Eric J Shiroma; Janet E Fulton Journal: Lancet Public Health Date: 2022-03
Authors: Cathie Sudlow; John Gallacher; Naomi Allen; Valerie Beral; Paul Burton; John Danesh; Paul Downey; Paul Elliott; Jane Green; Martin Landray; Bette Liu; Paul Matthews; Giok Ong; Jill Pell; Alan Silman; Alan Young; Tim Sprosen; Tim Peakman; Rory Collins Journal: PLoS Med Date: 2015-03-31 Impact factor: 11.069
Authors: Barbara J Jefferis; Tessa J Parsons; Claudio Sartini; Sarah Ash; Lucy T Lennon; Olia Papacosta; Richard W Morris; S Goya Wannamethee; I-Min Lee; Peter H Whincup Journal: Int J Cardiol Date: 2018-12-13 Impact factor: 4.164